Equities analysts expect NuVasive, Inc. (NASDAQ:NUVA) to report earnings per share (EPS) of $0.49 for the current quarter, Zacks reports. Five analysts have made estimates for NuVasive’s earnings. The lowest EPS estimate is $0.44 and the highest is $0.54. NuVasive reported earnings of $0.40 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 22.5%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, October 24th.

On average, analysts expect that NuVasive will report full-year earnings of $2.00 per share for the current fiscal year, with EPS estimates ranging from $1.95 to $2.05. For the next fiscal year, analysts forecast that the company will report earnings of $2.44 per share, with EPS estimates ranging from $2.40 to $2.55. Zacks’ EPS calculations are an average based on a survey of research analysts that cover NuVasive.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The business had revenue of $260.60 million during the quarter, compared to the consensus estimate of $261.95 million. During the same period in the previous year, the business earned $0.40 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis.

Several research firms have recently issued reports on NUVA. Royal Bank Of Canada restated a “buy” rating and set a $85.00 price objective on shares of NuVasive in a report on Thursday, July 20th. BidaskClub upgraded shares of NuVasive from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Jefferies Group LLC reiterated a “buy” rating and issued a $84.00 target price on shares of NuVasive in a research note on Friday, June 30th. Canaccord Genuity reiterated a “buy” rating and issued a $80.00 target price on shares of NuVasive in a research note on Friday, July 28th. Finally, Gabelli reissued a “buy” rating on shares of NuVasive in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $79.92.

In other NuVasive news, CEO Gregory T. Lucier purchased 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 29th. The shares were acquired at an average cost of $61.52 per share, for a total transaction of $123,040.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Gregory T. Lucier purchased 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average price of $66.22 per share, for a total transaction of $331,100.00. The disclosure for this purchase can be found here. Insiders have acquired 14,850 shares of company stock worth $955,598 over the last ninety days. Insiders own 1.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NUVA. FNY Partners Fund LP bought a new stake in shares of NuVasive during the first quarter worth $112,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock valued at $146,000 after buying an additional 158 shares during the last quarter. Howard Hughes Medical Institute raised its holdings in shares of NuVasive by 82.8% in the second quarter. Howard Hughes Medical Institute now owns 2,066 shares of the medical device company’s stock valued at $159,000 after buying an additional 936 shares during the last quarter. US Bancorp DE raised its holdings in shares of NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock valued at $180,000 after buying an additional 41 shares during the last quarter. Finally, Honkamp Krueger Financial Services Inc. bought a new position in shares of NuVasive in the second quarter valued at about $201,000.

Shares of NuVasive (NASDAQ:NUVA) opened at 54.44 on Wednesday. The firm has a market capitalization of $2.77 billion, a price-to-earnings ratio of 85.73 and a beta of 1.03. The company’s 50 day moving average price is $59.73 and its 200 day moving average price is $70.55. NuVasive has a 52-week low of $52.85 and a 52-week high of $81.68.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/zacks-brokerages-expect-nuvasive-inc-nuva-to-announce-0-49-earnings-per-share.html.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Get a free copy of the Zacks research report on NuVasive (NUVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.